A new study conducted by researchers from Monash University, published in Nutrients, shows that a tocotrienol-rich faction (here, EVNol SupraBio) has beneficial effects in ameliorating several metabolic syndrome related conditions after four weeks of supplementation.
Researchers conducted the study on 21 rats split into three groups: control, high-fat diet and tocotrienol-rich fraction (TRF). The control group received a low-fat diet, while the high-fat diet and TRF groups were given high-fat diets for eight weeks to induce metabolic syndrome. Subsequently, the TRF group was supplemented for four weeks with 60mg/kg of tocotrienol rich fraction of palm oil (Tocovid SupraBio) delivered in a 10 percent glucose solution. The control and high-fat diet groups were given just the 10 percent glucose solution for four weeks. At the end of the experiment, the rats underwent a 12-hour fasting before blood and tissue samples were collected, processed, and analysed.
The researchers found eight weeks of a high-fat diet induced metabolic syndrome in the rats, including diabetes mellitus. The subsequent TRF supplementation was shown to help reverse hypertension, hypercholesterolemia and fatty liver; inhibit protein glycation to reduced glycated haemoglobin A1c (HbA1c) and advanced glycation end products (AGE); and restore antioxidant capacity and reduce myeloperoxidase activities that may lead to oxidative stress. On the other hand, the researchers did not observe significant results in relation to visceral fat deposit, glucose level, plasma triglycerides or peroxisome proliferator-activated alpha and gamma expression.
The researchers concluded that TRF may have potential for metabolic syndrome therapy especially on cardiovascular and liver health, and therefore worth further investigation.
‘In addition to the potent antioxidant property of tocotrienol which plays an important role in restoring antioxidant capacity and attenuating oxidative stress in metabolic syndrome condition, this study provides exciting results that reveal the suppression of glycation by EVNol SupraBio, which may reduce glycated haemoglobin and AGE in the liver,’ said Bryan See, business development manager at ExcelVite. He added: ‘This mirrors the findings of our earlier human studies that show EVNol SupraBio is beneficial for maintaining healthy cholesterol level, supports healthy blood pressure, and improves fatty liver that collectively may reduce the risk for metabolic syndrome condition.’